Safety profile of anifrolumab in SLE patients


Manage episode 293955136 series 1426075
著作 BMJ talk medicine and BMJ Group の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Duane Peters from the Lupus Foundation of America interviews Professor Eric Morand from Monash University in Australia and Dr Raj Tummala from AstraZeneca in the USA about phase II and III trials of the human monoclonal antibody anifrolumab. Their pooled analysis of data from the MUSE, TULIP-1 and TULIP-2 trials showed that, in addition to demonstrating efficacy in adults with moderate to severe systemic lupus erythematosus (SLE), anifrolumab was generally well tolerated with an acceptable safety profile. Anifrolumab was associated with an increased incidence of herpes zoster and respiratory tract infections and a lower reported rate of SLE worsening. This positive benefit–risk profile means that anifrolumab is a potential new treatment option for SLE. Access the paper here:

3544 つのエピソード